

Press release for immediate release

## Genomtec secures fifth patent for its invention

Wrocław, Poland - October 28, 2021. - Genomtec S.A. "GMT," a NewConnect-listed medical technology company, has received notification from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) that it has received patent protection for its invention, which is a contactless heating and detection technology that can be used not only in genetic research, as in the case of patent No. 235210 held by the Company, but also in any other type of devices or control systems designed outside the medical industry. This is the fifth patent received by Genomtec since the Company's inception and the third issued by URPL.

*"The notice of patent protection we received today is particularly important to us. It highlights the possibility of using our technology not only in Genomtec®ID, but in other devices or systems, thus significantly increasing the Company's intellectual property and shareholder value."* - said Miron Tokarski, CEO and co-founder of Genomtec.

The subject of the new patent-protected invention is a kit for non-contact temperature control, a method of generating wave fronts of electromagnetic radiation and an application of the kit to generate temperature field profiles.

The patent proceedings are aimed at securing key licensing interests and are part of Genomtec's growth strategy, which includes building a portfolio of intellectual property rights. Strong intellectual property protection provides the Company with competitive advantage and improves negotiating position before signing commercial agreements with selected partners for the implementation of the commercialization strategy.

#####

### Dodatkowych informacji udziela:

Genomtec S.A.  
Magdalena Kicińska  
+48 604 201 230  
[m.kicinska@genomtec.com](mailto:m.kicinska@genomtec.com)

### About Genomtec S.A.

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate



design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wrocław.

More information at: [www.genomtec.com](http://www.genomtec.com)